NCT07506551

Brief Summary

Determination of proteins and their levels in the vitreous of eyes with or without pseudoexfoliation syndrome (PEX)

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
6mo left

Started Jul 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Jul 2023Dec 2026

Study Start

First participant enrolled

July 6, 2023

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

March 26, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 1, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

April 1, 2026

Status Verified

March 1, 2026

Enrollment Period

3 years

First QC Date

March 26, 2026

Last Update Submit

March 26, 2026

Conditions

Pseudoexfoliation Syndrome

Keywords

pseudoexfoliation syndromevitreousproteomics

Outcome Measures

Primary Outcomes (1)

  • Protein levels

    Protein levels in vitreous samples of patients with and without pseudoexfoliation syndrom will be meausred using Liquid chromatography mass spectrometry

    24 months

Study Arms (1)

Patients scheduled for vitrectomy

OTHER

Patients with epiretinal membranes or macular holes with or without pseudoexfoliation syndrome

Other: Liquid chromatography mass spectrometry

Interventions

Liquid chromatography mass spectrometryOTHER

Proteomic analysis of vitreous samples of patients with epiretinal membranes or macular holes with or without pseudoexfoliation syndrome using Liquid chromatography mass spectrometry

Patients scheduled for vitrectomy

Eligibility Criteria

Age21 Years - 105 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • PEX syndrome
  • Macular pucker or macular hole and scheduled for vitrectomy
  • Age 21 or older
  • Written informed consent prior to surgery

You may not qualify if:

  • Previous vitrectomy or intravitreal application of drugs
  • Systemic anti-inflammatory drugs
  • Pre- surgical topical anti-inflammatory drugs (NSAR, Steroids)
  • Pre- surgical topical prostaglandins
  • Diabetic retinopathy
  • AMD
  • PEX Syndrome only in the contralateral eye (the eye not scheduled for surgery)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vienna Institute for Research in Ocular Surgery (VIROS)

Vienna, 1140, Austria

Location

MeSH Terms

Conditions

Exfoliation Syndrome

Interventions

Liquid Chromatography-Mass Spectrometry

Condition Hierarchy (Ancestors)

Iris DiseasesUveal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Chromatography, LiquidChromatographyChemistry Techniques, AnalyticalInvestigative TechniquesMass Spectrometry

Study Officials

  • Oliver Findl, Prim. Univ. Prof. Dr.

    Vienna Institute for Research in Ocular Surgery (VIROS)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 26, 2026

First Posted

April 1, 2026

Study Start

July 6, 2023

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

April 1, 2026

Record last verified: 2026-03

Locations

AU(1)